Edge Therapeutics, a US-based biopharmaceutical company incubated at the New Jersey Institute of Technology, has raised $18m in its series C round.

Investment bank Maxim Group was the placement agent and financial adviser for the offering, which will fund a phase II study of its lead product candidate, EG-1962 (nimodipine microparticles), for the prevention of complications from bleeding.

In October 2010, the New Jersey Technology Council named Edge one of its four “incubator companies to watch”. 

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?